peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

neurohypophyseal hormone

Vasopressin

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

Vasopressin is categorized as a peptide (polypeptide) hormone, consistent with its amino-acid-based structure. Vasopressin’s antidiuretic effect is mediated through V2 receptor activation, which couples to adenyl cyclase signaling in renal pathways to promote antidiuresis. The product is contraindicated when there is a known hypersensitivity to the active peptide (8-L-arginine vasopressin) or the preservative chlorobutanol. For post-cardiotomy shock, the label provides an initial vasopressin infusion rate of 0.03 units/minute.

Sources for this introduction: [1] [2] [3] [4]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

This product contains synthetic vasopressin formulated as a sterile injectable solution intended for intramuscular or subcutaneous administration.

Sources[2]dailymedVASOPRESSIN INJECTION, USP (SYNTHETIC)Vasopressin Injection, USP is a sterile solution of synthetic vasopressin of the posterior pituitary gland for intramuscular (IM) or subcutaneous use.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Vasopressin Injection, USP is a sterile solution of synthetic vasopressin of the posterior pituitary gland for intramuscular (IM) or subcutaneous use.”

    VASOPRESSIN INJECTION, USP (SYNTHETIC) · DESCRIPTION:

    dailymed:40dab227-b05b-4e72-a59c-6e6f8a80252e:8c01a6d3fd13:8c01a6d3fd13

Identity

Vasopressin is categorized as a peptide (polypeptide) hormone, consistent with its amino-acid-based structure.

Sources[5]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Vasopressin is a polypeptide hormone.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Vasopressin is a polypeptide hormone.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 11 DESCRIPTION

    dailymed:caf04d72-679e-daf9-e86f-4867f83b8ac5:d10c771a18f0:d10c771a18f0

Identity

The product is an intravenous vasopressin solution (20 units/mL) supplied in single-dose vials and intended for use after dilution.

Sources[3]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection for intravenous useInitial U.S. Approval: 2014Vasopressin Injection, USP is a clear, practically colorless solution for intravenous administration available as 20 units/mL in a single dose vial. To be used after dilution.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Vasopressin Injection, USP is a clear, practically colorless solution for intravenous administration available as 20 units/mL in a single dose vial. To be used after dilution.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection for intravenous useInitial U.S. Approval: 2014 · 3 DOSAGE FORMS AND STRENGTHS

    dailymed:4e6c737d-65e8-4af4-b301-69a93affbc7f:be93c86101f0:be93c86101f0

Identity

The dosage forms include an IV solution at 20 units/mL packaged either as a single-dose 1 mL vial or as a multiple-dose 10 mL vial containing 200 units per 10 mL (20 units/mL).

Sources[1]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Vasopressin injection, USP is a clear, practically colorless solution for intravenous administration available as 20 units/mL in a single-dose vial and 200 units/10 mL (20 units/mL) in a multiple-dose vial.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Vasopressin injection, USP is a clear, practically colorless solution for intravenous administration available as 20 units/mL in a single-dose vial and 200 units/10 mL (20 units/mL) in a multiple-dose vial.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 3 DOSAGE FORMS AND STRENGTHS

    dailymed:0ab267f4-9ec9-44fd-8521-f975074667d9:1bf7840095ab:1bf7840095ab

Identity

The premixed IV formulation is supplied in three labeled strengths, each in 0.9% sodium chloride, enabling different infusion concentration options.

Sources[4]dailymedThese highlights do not include all the information needed to use VASOPRESSIN IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for VASOPRESSIN IN SODIUM CHLORIDE INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 201420 units/100 mL (0.2 units/mL) in 0.9% Sodium Chloride40 units/100 mL (0.4 units/mL) in 0.9% Sodium Chloride50 units/50 mL (1 unit/mL) in 0.9% Sodium Chloride
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “20 units/100 mL (0.2 units/mL) in 0.9% Sodium Chloride40 units/100 mL (0.4 units/mL) in 0.9% Sodium Chloride50 units/50 mL (1 unit/mL) in 0.9% Sodium Chloride”

    These highlights do not include all the information needed to use VASOPRESSIN IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for VASOPRESSIN IN SODIUM CHLORIDE INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 3 DOSAGE FORMS AND STRENGTHS

    dailymed:bf4b0b63-0055-40d8-b331-7f9f1ea3214c:e955d1be7b16:e955d1be7b16

How does it work?

Target, response, and disposition.

Mechanism

The vasoconstrictor action is mediated through V1 receptor activation on vascular smooth muscle with Gq/11-PLC-IP3 signaling leading to increased intracellular Ca2+.

Sources[4]dailymedThese highlights do not include all the information needed to use VASOPRESSIN IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for VASOPRESSIN IN SODIUM CHLORIDE INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Vasopressin causes vasoconstriction by binding to V1receptors on vascular smooth muscle coupled to the Gq/11-phospholipase C-phosphatidyl-inositol-triphosphate pathway, resulting in the release of intracellular calcium.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Vasopressin causes vasoconstriction by binding to V1receptors on vascular smooth muscle coupled to the Gq/11-phospholipase C-phosphatidyl-inositol-triphosphate pathway, resulting in the release of intracellular calcium.”

    These highlights do not include all the information needed to use VASOPRESSIN IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for VASOPRESSIN IN SODIUM CHLORIDE INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 12.1 Mechanism of Action

    dailymed:bf4b0b63-0055-40d8-b331-7f9f1ea3214c:e955d1be7b16:e955d1be7b16

Mechanism

Mechanistically, vasopressin’s vasoconstrictor action is mediated by V1 receptor activation on vascular smooth muscle, engaging Gq/11 signaling through phospholipase C and downstream phosphatidyl-inositol-triphosphate to raise intracellular calcium and contract smooth muscle.

Sources[5]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Vasopressin causes vasoconstriction by binding to V1receptors on vascular smooth muscle coupled to the Gq/11-phospholipase C-phosphatidyl-inositol-triphosphate pathway, resulting in the release of intracellular calcium.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Vasopressin causes vasoconstriction by binding to V1receptors on vascular smooth muscle coupled to the Gq/11-phospholipase C-phosphatidyl-inositol-triphosphate pathway, resulting in the release of intracellular calcium.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 12.1 Mechanism of Action

    dailymed:caf04d72-679e-daf9-e86f-4867f83b8ac5:d10c771a18f0:d10c771a18f0

Mechanism

Vasopressin’s antidiuretic effect is mediated through V2 receptor activation, which couples to adenyl cyclase signaling in renal pathways to promote antidiuresis.

Sources[5]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014In addition, vasopressin stimulates antidiuresis via stimulation of V2receptors which are coupled to adenyl cyclase.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “In addition, vasopressin stimulates antidiuresis via stimulation of V2receptors which are coupled to adenyl cyclase.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 12.1 Mechanism of Action

    dailymed:caf04d72-679e-daf9-e86f-4867f83b8ac5:d10c771a18f0:d10c771a18f0

Pharmacokinetics

Within the stated infusion-rate range (10–200 μU/kg/min), vasopressin shows linear pharmacokinetics with plasma concentrations increasing proportionally as infusion rate increases.

Sources[5]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Vasopressin plasma concentrations increase linearly with increasing infusion rates from 10 to 200 μU/kg/min.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Vasopressin plasma concentrations increase linearly with increasing infusion rates from 10 to 200 μU/kg/min.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 12.3 Pharmacokinetics

    dailymed:caf04d72-679e-daf9-e86f-4867f83b8ac5:d10c771a18f0:d10c771a18f0

Pharmacokinetics

Across the infusion-rate range of 10–200 microunits/kg/min, vasopressin exhibits linear (dose-proportional) increases in plasma concentration.

Sources[1]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Vasopressin plasma concentrations increase linearly with increasing infusion rates from 10 microunits/kg/min to 200 microunits/kg/min.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Vasopressin plasma concentrations increase linearly with increasing infusion rates from 10 microunits/kg/min to 200 microunits/kg/min.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 12.3 Pharmacokinetics

    dailymed:0ab267f4-9ec9-44fd-8521-f975074667d9:1bf7840095ab:1bf7840095ab

Pharmacokinetics

With continuous intravenous infusion, vasopressin reaches steady-state plasma concentrations by 30 minutes per the provided pharmacokinetic description.

Sources[5]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Steady state plasma concentrations are achieved after 30 minutes of continuous intravenous infusion.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Steady state plasma concentrations are achieved after 30 minutes of continuous intravenous infusion.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 12.3 Pharmacokinetics

    dailymed:caf04d72-679e-daf9-e86f-4867f83b8ac5:d10c771a18f0:d10c771a18f0

Pharmacokinetics

With continuous IV infusion, vasopressin reaches steady-state plasma concentration by 30 minutes, consistent with rapid attainment of equilibrium under constant infusion.

Sources[1]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Steady state plasma concentrations are achieved after 30 minutes of continuous intravenous infusion.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Steady state plasma concentrations are achieved after 30 minutes of continuous intravenous infusion.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 12.3 Pharmacokinetics

    dailymed:0ab267f4-9ec9-44fd-8521-f975074667d9:1bf7840095ab:1bf7840095ab

What has been studied?

What the evidence says.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Risks and interactions

Risks, organized for scanning.

Contraindications

A history of anaphylaxis or hypersensitivity to vasopressin (or formulation components) is listed as a contraindication.

Sources[2]dailymedVASOPRESSIN INJECTION, USP (SYNTHETIC)Anaphylaxis or hypersensitivity to the drug or its components.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Anaphylaxis or hypersensitivity to the drug or its components.”

    VASOPRESSIN INJECTION, USP (SYNTHETIC) · CONTRAINDICATIONS:

    dailymed:40dab227-b05b-4e72-a59c-6e6f8a80252e:8c01a6d3fd13:8c01a6d3fd13

Contraindications

The product is contraindicated for patients with hypersensitivity to the active peptide (8-L-arginine vasopressin) or the preservative chlorobutanol.

Sources[1]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Vasopressin injection 1 mL single-dose vial and 10 mL multiple-dose vial are contraindicated in patients with known allergy or hypersensitivity to 8-L-arginine vasopressin or chlorobutanol.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Vasopressin injection 1 mL single-dose vial and 10 mL multiple-dose vial are contraindicated in patients with known allergy or hypersensitivity to 8-L-arginine vasopressin or chlorobutanol.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 4 CONTRAINDICATIONS

    dailymed:0ab267f4-9ec9-44fd-8521-f975074667d9:1bf7840095ab:1bf7840095ab

Contraindications

Contraindication: known hypersensitivity to the active peptide (8‑L-arginine vasopressin) or the preservative chlorobutanol.

Sources[3]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection for intravenous useInitial U.S. Approval: 2014Vasopressin Injection, USP 1 mL single dose vial is contraindicated in patients with known allergy or hypersensitivity to 8‑L-arginine vasopressin or chlorobutanol.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Vasopressin Injection, USP 1 mL single dose vial is contraindicated in patients with known allergy or hypersensitivity to 8‑L-arginine vasopressin or chlorobutanol.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection for intravenous useInitial U.S. Approval: 2014 · 4 CONTRAINDICATIONS

    dailymed:4e6c737d-65e8-4af4-b301-69a93affbc7f:be93c86101f0:be93c86101f0

Contraindications

The product is contraindicated when there is a known hypersensitivity to the active peptide (8-L-arginine vasopressin) or the preservative chlorobutanol.

Sources[4]dailymedThese highlights do not include all the information needed to use VASOPRESSIN IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for VASOPRESSIN IN SODIUM CHLORIDE INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Vasopressin in Sodium Chloride Injection is contraindicated in patients with known allergy or hypersensitivity to 8-L-arginine vasopressin or chlorobutanol.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Vasopressin in Sodium Chloride Injection is contraindicated in patients with known allergy or hypersensitivity to 8-L-arginine vasopressin or chlorobutanol.”

    These highlights do not include all the information needed to use VASOPRESSIN IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for VASOPRESSIN IN SODIUM CHLORIDE INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 4 CONTRAINDICATIONS

    dailymed:bf4b0b63-0055-40d8-b331-7f9f1ea3214c:e955d1be7b16:e955d1be7b16

Safety findings

A discontinuation-associated adverse effect described is reversible diabetes insipidus, clinically presenting with increased urine output, low urine concentration, and elevated serum sodium.

Sources[4]dailymedThese highlights do not include all the information needed to use VASOPRESSIN IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for VASOPRESSIN IN SODIUM CHLORIDE INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Patients may experience reversible diabetes insipidus, manifested by the development of polyuria, a dilute urine, and hypernatremia, after cessation of treatment with vasopressin.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Patients may experience reversible diabetes insipidus, manifested by the development of polyuria, a dilute urine, and hypernatremia, after cessation of treatment with vasopressin.”

    These highlights do not include all the information needed to use VASOPRESSIN IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for VASOPRESSIN IN SODIUM CHLORIDE INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 5.2 Reversible Diabetes Insipidus

    dailymed:bf4b0b63-0055-40d8-b331-7f9f1ea3214c:e955d1be7b16:e955d1be7b16

Products and regulatory status

Same ingredient. Different records.

Regulatory status

The indicated use is as a vasopressor for adult vasodilatory shock that persists despite adequate volume resuscitation and catecholamine therapy.

Sources[1]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 1 INDICATIONS AND USAGE

    dailymed:0ab267f4-9ec9-44fd-8521-f975074667d9:1bf7840095ab:1bf7840095ab

Regulatory status

The labeled indication is pressor support: increasing blood pressure in adult vasodilatory shock refractory to fluids and catecholamines.

Sources[4]dailymedThese highlights do not include all the information needed to use VASOPRESSIN IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for VASOPRESSIN IN SODIUM CHLORIDE INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.”

    These highlights do not include all the information needed to use VASOPRESSIN IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for VASOPRESSIN IN SODIUM CHLORIDE INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 1 INDICATIONS AND USAGE

    dailymed:bf4b0b63-0055-40d8-b331-7f9f1ea3214c:e955d1be7b16:e955d1be7b16

Regulatory status

In adult vasodilatory shock refractory to fluids and catecholamines, vasopressin injection is indicated as a pressor to increase blood pressure.

Sources[3]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection for intravenous useInitial U.S. Approval: 2014Vasopressin Injection, USP is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Vasopressin Injection, USP is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection for intravenous useInitial U.S. Approval: 2014 · 1 INDICATIONS AND USAGE

    dailymed:4e6c737d-65e8-4af4-b301-69a93affbc7f:be93c86101f0:be93c86101f0

Regulatory status

The labeled uses include prevention/treatment of postoperative abdominal distention, use in abdominal roentgenography to dispel interfering gas shadows, and treatment of diabetes insipidus.

Sources[2]dailymedVASOPRESSIN INJECTION, USP (SYNTHETIC)Vasopressin Injection, USP is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows and in diabetes insipidus.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Vasopressin Injection, USP is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows and in diabetes insipidus.”

    VASOPRESSIN INJECTION, USP (SYNTHETIC) · INDICATIONS AND USAGE:

    dailymed:40dab227-b05b-4e72-a59c-6e6f8a80252e:8c01a6d3fd13:8c01a6d3fd13

Regulatory status

The labeled indication for vasopressin injection is treatment of persistent hypotension in adult vasodilatory shock by increasing blood pressure despite prior fluid resuscitation and catecholamine support.

Sources[5]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 1 INDICATIONS AND USAGE

    dailymed:caf04d72-679e-daf9-e86f-4867f83b8ac5:d10c771a18f0:d10c771a18f0

Administration context

The practical clinical context.

Administration

The stability/handling instruction for diluted vasopressin is time- and temperature-limited: discard remaining diluted solution after 18 hours at room temperature or 24 hours refrigerated.

Sources[5]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 2.1 Preparation of Solution

    dailymed:caf04d72-679e-daf9-e86f-4867f83b8ac5:d10c771a18f0:d10c771a18f0

Administration

Diluted vasopressin has time-dependent stability limits: discard after 18 hours at room temperature or 24 hours when refrigerated.

Sources[3]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection for intravenous useInitial U.S. Approval: 2014Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection for intravenous useInitial U.S. Approval: 2014 · 2.1 Preparation of Solution

    dailymed:4e6c737d-65e8-4af4-b301-69a93affbc7f:be93c86101f0:be93c86101f0

Administration

For intravenous administration, vasopressin injection requires dilution in compatible diluents (0.9% sodium chloride or 5% dextrose in water).

Sources[3]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection for intravenous useInitial U.S. Approval: 2014Dilute Vasopressin Injection, USP in normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) prior to use for intravenous administration.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Dilute Vasopressin Injection, USP in normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) prior to use for intravenous administration.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection for intravenous useInitial U.S. Approval: 2014 · 2.1 Preparation of Solution

    dailymed:4e6c737d-65e8-4af4-b301-69a93affbc7f:be93c86101f0:be93c86101f0

Administration

The prepared (diluted) infusion solution has a limited in-use stability window: 18 hours at room temperature or 24 hours under refrigeration, after which it should be discarded.

Sources[1]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 2.1 Preparation of Diluted Solutions

    dailymed:0ab267f4-9ec9-44fd-8521-f975074667d9:1bf7840095ab:1bf7840095ab

Administration

The product is provided in a form that requires no additional dilution step prior to administration.

Sources[4]dailymedThese highlights do not include all the information needed to use VASOPRESSIN IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for VASOPRESSIN IN SODIUM CHLORIDE INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014This product does not require further dilution prior to administration.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “This product does not require further dilution prior to administration.”

    These highlights do not include all the information needed to use VASOPRESSIN IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for VASOPRESSIN IN SODIUM CHLORIDE INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 2.1 Preparation of Solution

    dailymed:bf4b0b63-0055-40d8-b331-7f9f1ea3214c:e955d1be7b16:e955d1be7b16

Administration

For intravenous infusion, the product should be prepared by dilution using either normal saline (0.9% Sodium Chloride Injection) or 5% Dextrose Injection as the diluent.

Sources[1]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Dilute vasopressin injection in 0.9% Sodium Chloride Injection or 5% Dextrose Injection prior to use for intravenous infusion.[5]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Dilute vasopressin injection in normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) prior to use for intravenous administration.
Source records
2
Regulatory records
2

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Dilute vasopressin injection in 0.9% Sodium Chloride Injection or 5% Dextrose Injection prior to use for intravenous infusion.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 2.1 Preparation of Diluted Solutions

    dailymed:0ab267f4-9ec9-44fd-8521-f975074667d9:1bf7840095ab:1bf7840095ab
  2. supports · Source-backed record
    “Dilute vasopressin injection in normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) prior to use for intravenous administration.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 2.1 Preparation of Solution

    dailymed:caf04d72-679e-daf9-e86f-4867f83b8ac5:d10c771a18f0:d10c771a18f0

Dose records

The prescribing information specifies different initial continuous-infusion rates by shock etiology: higher for post-cardiotomy shock (0.03 units/minute) and lower for septic shock (0.01 units/minute).

Sources[5]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014The recommended starting dose is:Post-cardiotomy shock:0.03 units/minuteSeptic Shock:0.01 units/minute
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The recommended starting dose is:Post-cardiotomy shock:0.03 units/minuteSeptic Shock:0.01 units/minute”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 2.2 Administration

    dailymed:caf04d72-679e-daf9-e86f-4867f83b8ac5:d10c771a18f0:d10c771a18f0

Dose records

The preparation is potency-standardized at 20 pressor units per milliliter, indicating a defined vasopressor unit content per volume.

Sources[2]dailymedVASOPRESSIN INJECTION, USP (SYNTHETIC)It is substantially free from the oxytocic principle and is standardized to contain 20 pressor units/mL.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “It is substantially free from the oxytocic principle and is standardized to contain 20 pressor units/mL.”

    VASOPRESSIN INJECTION, USP (SYNTHETIC) · DESCRIPTION:

    dailymed:40dab227-b05b-4e72-a59c-6e6f8a80252e:8c01a6d3fd13:8c01a6d3fd13

Dose records

Dose escalation guidance for vasopressin infusion is stepwise titration: increase the infusion rate by 0.005 units/minute at 10–15 minute intervals, guided by achievement of target blood pressure.

Sources[5]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Titrate up by 0.005 units/minute at 10 -to 15-minute intervals until the target blood pressure is reached.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Titrate up by 0.005 units/minute at 10 -to 15-minute intervals until the target blood pressure is reached.”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 2.2 Administration

    dailymed:caf04d72-679e-daf9-e86f-4867f83b8ac5:d10c771a18f0:d10c771a18f0

Dose records

Initial continuous-infusion dosing differs by shock etiology: higher starting rate for post-cardiotomy shock (0.03 units/minute) and lower for septic shock (0.01 units/minute).

Sources[1]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014The recommended starting dose is:Post-cardiotomy shock: 0.03 units/minuteSeptic Shock:0.01 units/minute
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The recommended starting dose is:Post-cardiotomy shock: 0.03 units/minuteSeptic Shock:0.01 units/minute”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 2.2 Administration

    dailymed:0ab267f4-9ec9-44fd-8521-f975074667d9:1bf7840095ab:1bf7840095ab

Dose records

For septic shock, the label recommends initiating vasopressin as a continuous infusion at 0.01 units/minute.

Sources[4]dailymedThese highlights do not include all the information needed to use VASOPRESSIN IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for VASOPRESSIN IN SODIUM CHLORIDE INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Septic Shock:0.01 units/minute by intravenous infusion
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Septic Shock:0.01 units/minute by intravenous infusion”

    These highlights do not include all the information needed to use VASOPRESSIN IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for VASOPRESSIN IN SODIUM CHLORIDE INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 2.2 Administration

    dailymed:bf4b0b63-0055-40d8-b331-7f9f1ea3214c:e955d1be7b16:e955d1be7b16

Dose records

For septic shock, vasopressin is started as a continuous infusion at 0.01 units per minute.

Sources[3]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection for intravenous useInitial U.S. Approval: 2014Septic Shock:0.01 units/minute
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Septic Shock:0.01 units/minute”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection for intravenous useInitial U.S. Approval: 2014 · 2.2 Administration

    dailymed:4e6c737d-65e8-4af4-b301-69a93affbc7f:be93c86101f0:be93c86101f0

Dose records

For post-cardiotomy shock, the label provides an initial vasopressin infusion rate of 0.03 units/minute.

Sources[4]dailymedThese highlights do not include all the information needed to use VASOPRESSIN IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for VASOPRESSIN IN SODIUM CHLORIDE INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014Post-cardiotomy shock:0.03 units/minute by intravenous infusion
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Post-cardiotomy shock:0.03 units/minute by intravenous infusion”

    These highlights do not include all the information needed to use VASOPRESSIN IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for VASOPRESSIN IN SODIUM CHLORIDE INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 · 2.2 Administration

    dailymed:bf4b0b63-0055-40d8-b331-7f9f1ea3214c:e955d1be7b16:e955d1be7b16

Dose records

For post-cardiotomy shock, vasopressin is started as a continuous infusion at 0.03 units per minute.

Sources[3]dailymedThese highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection for intravenous useInitial U.S. Approval: 2014Post-cardiotomy shock:0.03 units/minute
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Post-cardiotomy shock:0.03 units/minute”

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection for intravenous useInitial U.S. Approval: 2014 · 2.2 Administration

    dailymed:4e6c737d-65e8-4af4-b301-69a93affbc7f:be93c86101f0:be93c86101f0

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: effect, interaction
  • 24 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (10), assurance_score_below_0.72 (14), current_regulatory_source_required (9), extraction_ambiguity (25), high_risk_requires_regulatory_or_two_independent_sources (14), no_direct_support (24)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 ↗

    dailymed · published 2024-10-31 · retrieved 2026-09-04T22:25:30Z

  2. VASOPRESSIN INJECTION, USP (SYNTHETIC) ↗

    dailymed · published 2017-01-23 · retrieved 2026-09-04T22:25:28Z

  3. These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection for intravenous useInitial U.S. Approval: 2014 ↗

    dailymed · published 2022-08-22 · retrieved 2026-09-04T22:25:30Z

  4. These highlights do not include all the information needed to use VASOPRESSIN IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for VASOPRESSIN IN SODIUM CHLORIDE INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 ↗

    dailymed · published 2025-06-17 · retrieved 2026-09-04T22:25:29Z

  5. These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.VASOPRESSIN injection, for intravenous useInitial U.S. Approval: 2014 ↗

    dailymed · published 2024-07-31 · retrieved 2026-09-04T22:25:28Z

Publication history and provenance

Version 3 · Automated assessment · 2026-09-04T22:25:30Z

a822d71e1172ecaa4fd4e8edc21f30f2d96333c999f92508279f7c00d457738b